Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Insider Sells $123,100.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Rating) insider Shafique Virani sold 10,000 shares of the company’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $12.31, for a total value of $123,100.00. Following the completion of the transaction, the insider now directly owns 83,160 shares in the company, valued at $1,023,699.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shafique Virani also recently made the following trade(s):

  • On Friday, October 14th, Shafique Virani sold 10,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.92, for a total value of $109,200.00.
  • On Thursday, September 15th, Shafique Virani sold 10,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $13.36, for a total value of $133,600.00.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $9.82 on Friday. The business’s 50-day simple moving average is $11.01 and its 200-day simple moving average is $9.25. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.92 and a 52 week high of $21.19.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Advisory Research Inc. boosted its stake in Recursion Pharmaceuticals by 56.6% during the 3rd quarter. Advisory Research Inc. now owns 96,803 shares of the company’s stock valued at $1,030,000 after purchasing an additional 34,999 shares during the period. BNP Paribas Arbitrage SNC bought a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at approximately $1,139,000. State Street Corp lifted its position in shares of Recursion Pharmaceuticals by 114.3% in the 3rd quarter. State Street Corp now owns 4,555,759 shares of the company’s stock worth $48,473,000 after acquiring an additional 2,430,027 shares during the period. UBS Asset Management Americas Inc. lifted its position in shares of Recursion Pharmaceuticals by 49.4% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 76,879 shares of the company’s stock worth $818,000 after acquiring an additional 25,426 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Recursion Pharmaceuticals by 19.9% in the 3rd quarter. Vanguard Group Inc. now owns 8,380,986 shares of the company’s stock worth $89,174,000 after acquiring an additional 1,393,519 shares during the period. Institutional investors own 54.16% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. KeyCorp assumed coverage on Recursion Pharmaceuticals in a research report on Thursday, September 15th. They issued an “overweight” rating and a $20.00 target price on the stock. The Goldman Sachs Group increased their price objective on Recursion Pharmaceuticals from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Wednesday, November 9th. Finally, SVB Leerink lowered their price objective on Recursion Pharmaceuticals from $10.00 to $9.00 and set a “market perform” rating on the stock in a report on Tuesday, October 25th.

About Recursion Pharmaceuticals

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.

Featured Articles

Insider Buying and Selling by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.